First Department of Gynecology and Obstetrics, Wroclaw Medical University, 50-368 Wrocław, Poland.
Second Department of Obstetrics and Gynecology, The Center of Postgraduate Medical Education, 01-809 Warsaw, Poland.
Int J Mol Sci. 2019 Mar 6;20(5):1136. doi: 10.3390/ijms20051136.
Uterine leiomyomas (LMs), currently the most common gynecological complaint around the world, are a serious medical, social and economic problem. Accurate diagnosis is the necessary prerequisite of the diagnostic-therapeutic process. Statistically, mistakes may occur more often in case of disease entities with high prevalence rates. Histopathology, based on increasingly advanced immunohistochemistry methods, is routinely used in the diagnosis of neoplastic diseases. Markers of the highest sensitivity and specificity profiles are used in the process. As far as LMs are concerned, the crux of the matter is to identify patients with seemingly benign lesions which turn out to be suspicious (e.g., atypical LM) or malignant (e.g., leiomyosarcoma (LMS)), which is not uncommon. In this study, we present the current state of knowledge about the use of immunohistochemical markers in the differential diagnosis of LM, atypical LM, smooth muscle tumors of uncertain malignant potential (STUMP), and LMS, as well as their clinical predictive value.
子宫肌瘤（LMs）是目前全世界最常见的妇科疾病之一，是一个严重的医学、社会和经济问题。准确的诊断是诊断-治疗过程的必要前提。从统计学的角度来看，在高发病率的疾病实体中，错误可能更经常发生。基于越来越先进的免疫组织化学方法的组织病理学在肿瘤疾病的诊断中常规使用。在这个过程中，使用具有最高敏感性和特异性特征的标志物。就 LMs 而言，关键是要识别出看似良性的病变，这些病变结果是可疑的（例如，非典型 LMs）或恶性的（例如，平滑肌肉瘤（LMS）），这种情况并不少见。在这项研究中，我们介绍了目前关于免疫组织化学标志物在 LMs、非典型 LMs、恶性潜能不确定的平滑肌肿瘤（STUMP）和 LMS 的鉴别诊断中的应用，以及它们的临床预测价值。
